MediWound (MDWD) Misses Q2 EPS by 8c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. WDAY
2. NVDA
3. META
4. JNJ
5. AAPL
6. AMAT
7. SPY
8. ASML
9. NRIX
10. SUNS

Go back to MediWound (MDWD) Misses Q2 EPS by 8c, Revenues Miss

MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 6, 2020 7:01 AM EDT

Submitted Biological License Application to the FDA for NexoBrid 
EscharEx U.S. Phase 2 Study Resumed Patient Screening

YAVNE, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the Company), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced financial results for the second quarter ended June 30, 2020 and provided business and financial updates related to the COVID-19 pandemic. 

Second Quarter Business and Financial Highlights:

Revenues for the second quarter of 2020 were $4.0... More